#USA #Boston #CARB-X #AdJane #Gonorrhea Vaccine

CARB-X Advances Gonorrhea Vaccine Development

The fight against antibiotic-resistant infections is sharper than ever, as the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) allocates $2.6 million to the Netherlands-based company AdJane. This funding aims to propel the advancement of a vaccine designed to prevent infections by Neisseria gonorrhoeae, the bacterium responsible for gonorrhea, which reports over 80 million new cases yearly worldwide.

Gonorrhea is a bacterial infection transmitted through sexual contact, with a growing concern due to its complications, including pelvic inflammatory disease, infertility, and an increased vulnerability to HIV. Adding to this, the nature of N. gonorrhoeae means it does not generate enduring natural immunity, making reinfection common and creating a problematic cycle of antibiotic treatment and resistance.

Richard Alm, interim Chief of Research and Development at CARB-X, notes the mounting complexities in managing gonorrhea cases due to escalating antibiotic resistance and a narrow selection of treatment options. He emphasized that AdJane’s innovative approach aims to solve these pressing challenges.

AdJane integrates its native Outer Membrane Vesicle (nOMV) platform to tackle antimicrobial resistance while enhancing global health outcomes. Drawing from a completed Phase I clinical trial, which showed a favorable safety profile for humans, the nOMV platform applies a heterologous methodology. This involves mixing a broad antigenic background with multiple highly conserved antigens specific to gonococcal infections. The goal is to generate a comprehensive immune response against N. gonorrhoeae, providing both breadth and focus in its effectiveness.

"Joining the CARB-X portfolio is a fantastic opportunity for us," stated Anita Gashi, Managing Director at AdJane. "This support propels our ambition to address antimicrobial resistance head-on. Our exciting heterologous approach showcases a novel vaccine construct engineered for effective immune response and streamlined development processes.”

This funding is a continuation of an earlier support initiative from CARB-X, intended to expedite the creation of a vaccine to combat gonorrhea. Since its establishment in 2016, CARB-X has been at the forefront of revitalizing the sluggish early-stage antibiotic pipeline. It has backed 123 research and development initiatives across 14 nations, fostering significant advancements, with 25 projects having entered or completed clinical trials and three products successfully launched in the market.

Moreover, CARB-X’s funding comes from a diverse consortium, including federal sources like the U.S. Department of Health and Human Services, other global health organizations, and private foundations. This collaborative financing model helps ensure that the supported projects adhere to global public health needs while considering responsible access and stewardship of the resulting products, especially in low and middle-income countries.

The collaborative spirit at the heart of CARB-X extends to all its product developers, each of whom must devise a stewardship and access plan addressing how to ensure their products are responsibly developed and distributed, reflecting a commitment to global health standards.

As the world increasingly grapples with the threats posed by antimicrobial resistance, initiatives like AdJane's vaccine development could mark a notable stride towards combatting bacterial infections effectively and improving public health across populations threatened by this challenging medical dilemma. By addressing gonorrhea, one of the most prevalent sexually transmitted infections today, the implications of this funding stretch far beyond the laboratory, engaging communities worldwide in the broader quest for healthier futures.